Table 4. Rates of HCV RNA undetectability during treatment stratified by ITPA deficiency.
No ITPA Deficiency (n = 48) | Mild ITPA Deficiency (n = 12) | Moderate ITPA deficiency (n = 9) | P * | |
Undetectable HCV-RNA | ||||
Week 4, n(%) | 21 (44%) | 6 (50%) | 3 (33%) | 0,79 |
Week 8, n(%) | 39 (81%) | 10 (83%) | 9 (100%) | 0,48 |
Week 12, n(%) | 38 (79%) | 10 (83%) | 9 (100%) | 0,32 |
*No ITPA deficiency versus any ITPA deficiency.